Oaktree Capital Group Holdings GP, LLC - 31 Mar 2025 SCHEDULE 13G/A Report for BioXcel Therapeutics, Inc. Common Stock, par value $0.001 per share (BTAI)

Filing Manager
Oaktree Capital Group Holdings GP, LLC
Reporting Manager
Oaktree Capital Holdings, LLC
Security
BioXcel Therapeutics, Inc. Common Stock, par value $0.001 per share
Symbol
BTAI
Shares outstanding
6,235,531 shares
Disclosed Ownership
170,230 shares
Ownership
2.7%
Form type
SCHEDULE 13G/A
Filing time
15 May 2025, 16:15:15 UTC
Date of event
31 Mar 2025
Previous filing
18 Dec 2024
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"Oaktree Capital Group Holdings GP, LLC disclosed 2.7% ownership in BioXcel Therapeutics, Inc. Common Stock, par value $0.001 per share (BTAI) on 31 Mar 2025."

Quick Takeaways

  • Oaktree Capital Group Holdings GP, LLC filed SCHEDULE 13G/A for BioXcel Therapeutics, Inc. Common Stock, par value $0.001 per share (BTAI).
  • Disclosed ownership: 2.7%.
  • Date of event: 31 Mar 2025.

What Changed

  • Previous schedule filing date: 18 Dec 2024.
  • Current filing was accepted on 15 May 2025, 16:15.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Official SEC Source

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (4)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Oaktree Fund Advisors, LLC 0.83% 51,429 0 51,429 /s/ Henry Orren Henry Orren, Authorized Signatory
Oaktree Capital Management LP 1.9% 118,801 0 118,801 /s/ Henry Orren Henry Orren, Authorized Signatory
Oaktree Capital Holdings, LLC 2.7% 170,230 0 170,230 /s/ Henry Orren Henry Orren, Authorized Signatory
Oaktree Capital Group Holdings GP, LLC 2.7% 170,230 0 170,230 /s/ Henry Orren Henry Orren, Authorized Signatory

Sponsored